381 related articles for article (PubMed ID: 24483346)
1. Staging and prognostication of multiple myeloma.
Fonseca R; Monge J; Dimopoulos MA
Expert Rev Hematol; 2014 Feb; 7(1):21-31. PubMed ID: 24483346
[TBL] [Abstract][Full Text] [Related]
2. Myeloma: classification and risk assessment.
Fonseca R; Monge J
Semin Oncol; 2013 Oct; 40(5):554-66. PubMed ID: 24135400
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
Chan NC; Chan NP
Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
[TBL] [Abstract][Full Text] [Related]
5. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
6. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
Mikhael JR; Dingli D; Roy V; Reeder CB; Buadi FK; Hayman SR; Dispenzieri A; Fonseca R; Sher T; Kyle RA; Lin Y; Russell SJ; Kumar S; Bergsagel PL; Zeldenrust SR; Leung N; Drake MT; Kapoor P; Ansell SM; Witzig TE; Lust JA; Dalton RJ; Gertz MA; Stewart AK; Rajkumar SV; Chanan-Khan A; Lacy MQ;
Mayo Clin Proc; 2013 Apr; 88(4):360-76. PubMed ID: 23541011
[TBL] [Abstract][Full Text] [Related]
7. Novel biomarkers in multiple myeloma.
Levin A; Hari P; Dhakal B
Transl Res; 2018 Nov; 201():49-59. PubMed ID: 30301522
[TBL] [Abstract][Full Text] [Related]
8. The impact of genomics on the management of myeloma.
Corre J; Avet-Loiseau H
J Natl Compr Canc Netw; 2011 Oct; 9(10):1200-6. PubMed ID: 21975916
[TBL] [Abstract][Full Text] [Related]
9. Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.
Shah V; Sherborne AL; Johnson DC; Ellis S; Price A; Chowdhury F; Kendall J; Jenner MW; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Davies FE; Cook G; Cairns DA; Houlston RS; Jackson G; Kaiser MF;
Leukemia; 2020 Nov; 34(11):3091-3096. PubMed ID: 32157174
[No Abstract] [Full Text] [Related]
10. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
11. [Classification and genetic abnormalities of multiple myeloma].
Hanamura I; Iida S
Nihon Rinsho; 2015 Jan; 73(1):17-27. PubMed ID: 25626298
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
Zhou P; Li W; Zuo S; Ma R; Yuan X; Zhu Z
Leuk Lymphoma; 2023; 64(8):1373-1388. PubMed ID: 37300424
[TBL] [Abstract][Full Text] [Related]
13. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
[TBL] [Abstract][Full Text] [Related]
14. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
[TBL] [Abstract][Full Text] [Related]
15. Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
[TBL] [Abstract][Full Text] [Related]
16. Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?
Mian HS; Wildes TM
Drugs Aging; 2018 Apr; 35(4):289-302. PubMed ID: 29557059
[TBL] [Abstract][Full Text] [Related]
17. Improving induction therapy in multiple myeloma.
Nooka A; Gleason C; Lonial S
Curr Hematol Malig Rep; 2010 Jul; 5(3):119-28. PubMed ID: 20449692
[TBL] [Abstract][Full Text] [Related]
18. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
19. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.
Johnson SK; Heuck CJ; Albino AP; Qu P; Zhang Q; Barlogie B; Shaughnessy JD
Int J Hematol; 2011 Oct; 94(4):321-333. PubMed ID: 22002477
[TBL] [Abstract][Full Text] [Related]
20. Multiple Myeloma Genomics - A Concise Review.
Castaneda O; Baz R
Acta Med Acad; 2019 Apr; 48(1):57-67. PubMed ID: 31264433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
